# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Georgia O'Keeffe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET011-SYN-TD
- Date: 1968-03-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wendell Ashby, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Retina evaluation of new distortion and blur in the left eye. **S**

## History of present illness

Ms. O'Keeffe is seen in the retina clinic two days after her primary care visit, where new distortion and a blurred central spot in the left eye were found on the Amsler grid. Over the past few weeks straight lines on her canvases and door frames have looked bent with the left eye, and small print and fine color differences have become hard to judge. The right eye seems unchanged. She has had no eye pain, redness, flashes, or new floaters. She takes no blood thinners and no other medicines. She paints daily and is afraid of losing the central vision she needs for her work. **S**

| Element | Detail |
|---|---|
| Onset | Over the past few weeks |
| Symptoms | Bent lines and a central blurred spot, left eye; trouble with small print and fine color differences |
| Fellow eye | No change noticed in the right eye |
| Pertinent negatives | No pain, redness, flashes, or new floaters |
| Medicines | None; no anticoagulants |
| Patient concern | Keeping the central vision she needs to paint |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Distortion and a central blurred spot in the left eye; no pain, redness, flashes, or floaters |
| Constitutional | Negative | No weight loss or fatigue |
| Neurological | Negative | No headache, double vision, or weakness |
| Psychiatric | Positive | Worried about losing the vision she needs to paint; mood otherwise steady |

4 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/72 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 56 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Best-corrected visual acuity, right eye (ETDRS letters): 78 (low); Best-corrected visual acuity, left eye (ETDRS letters): 55 (low); Central subfield thickness by OCT, left eye: 418 um (high); Intraocular pressure, right eye: 15 mmHg; Intraocular pressure, left eye: 16 mmHg. All results are synthetic.

## Change since baseline

- Best-corrected visual acuity, right eye (ETDRS letters): 78 (low) at baseline, 78 (low) at this visit **S**
- Best-corrected visual acuity, left eye (ETDRS letters): 56 (low) at baseline, 55 (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| Visual acuity | Best-corrected 78 letters right and 55 letters left |
| Intraocular pressure | 15 mmHg right and 16 mmHg left before injection |
| Anterior segment | Quiet in both eyes |
| Dilated fundus, left eye | Gray-green subretinal lesion under the fovea with surrounding fluid; large drusen |
| Dilated fundus, right eye | Large drusen and pigment changes; no fluid or hemorrhage |
| OCT | Left eye: subretinal fluid, central subfield thickness 418 µm. Both eyes: large drusen |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Neovascular age-related macular degeneration, left eye, active** (H35.3221). New subfoveal choroidal neovascularization with subretinal fluid on OCT (central subfield thickness 418 µm) and acuity reduced to 55 letters. First intravitreal aflibercept 2 mg injection given today without complication. **S**
   - Aflibercept 2 mg every four weeks for three loading doses, then treat-and-extend while the macula stays dry.
   - Return in four weeks for acuity, OCT, pressure, and the second injection.
   - Call the same day for pain, increasing redness, worsening vision, light sensitivity, or a curtain over the vision.
2. **Intermediate dry age-related macular degeneration, right eye** (H35.3112). Large drusen with no neovascularization. This eye now carries most of her reading and driving vision. **S**
   - Start the AREDS2 supplement daily (vitamin C, vitamin E, lutein, zeaxanthin, zinc, and copper; no beta-carotene).
   - Daily Amsler grid checks of each eye, with a same-day call for any new distortion.
   - Dilated examination of the right eye at each retina visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | Baseline before treatment: 78 letters right, 55 letters left |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Both eyes. Left: subretinal fluid, central subfield thickness 418 µm. Both: large drusen |
| Imaging | Fluorescein angiography or OCT angiography | At diagnosis of suspected neovascular AMD | Deferred | Not performed. OCT and fundus findings were typical, so treatment began the same day without angiography, a departure from the PPP's diagnostic recommendation. Angiography will be done if the response to loading is poor or the picture becomes atypical |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 15 mmHg right and 16 mmHg left. After injection the check was by optic nerve perfusion and counting fingers rather than a second pressure reading |
| Examination | Comprehensive dilated eye examination | Every 1 to 2 years at 65 or older | Completed today | Acuity, pressure, slit-lamp, and dilated fundus examination of both eyes today |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen; no fluid or hemorrhage |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | Povidone-iodine preparation; no complication; first loading dose |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Taught today with written instructions in large print |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Reviewed her technique with each eye covered in turn |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Started today; the formula without beta-carotene |
| Survey | Functional vision assessment (reading, color, driving, work) | At diagnosis; again with change | Completed today | Trouble with small print and fine color judgment; drives short routes by day |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Referred | Referral sent today |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Due | Score 1 two days ago; repeat at the July primary care review |

## Goal progress

- Gain at least 10 ETDRS letters in the left eye by the end of the loading phase. In progress; target 1968-05-07. **S**
- Dry macula on OCT (central subfield thickness below 300 um, no fluid) by the end of the loading phase. In progress; target 1968-05-07. **S**
- Check the Amsler grid daily for each eye and report any change the same day. In progress; target 1968-07-02. **S**
- Complete a low-vision rehabilitation evaluation and set up studio lighting and magnification by the July visit. In progress; target 1968-07-02. **S**

## Guideline basis

- Age-Related Macular Degeneration Preferred Practice Pattern (2024), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026), Aether Forge

## Follow-up

- Retina visit in four weeks for acuity, OCT, pressure, and the second injection. Same-day call for warning signs or new distortion in either eye. **S**
- Next scheduled visit 1968-04-09: four-week retina follow-up with OCT and second injection. **S**
